Firms claim technology can be exploited for fragment-based screens and kinetic profiling.
BioFocus and Almac have inked an agreement that will allow BioFocus to offer its customers compound screening and profiling services using Almac’s Flexyte™ fluorescence lifetime (FLT) assays. The firm has launched an FLT screening and profiling service using the Flexyte platform, for targets including proteases, phosphatases, and kinases. It says the Flexyte platform can be exploited for applications including fragment-based screens and kinetic profiling.
“Being able to incorporate FLT in our service offering enables BioFocus to provide clients with an approach to screening and profiling that will unlock significant potential within their drug discovery efforts,” comments Kate Hilyard, vp biological sciences.
Almac claims the Flexyte approach harnesses fluorescence lifetime technology that negates the need for radioactivity and antibodies, to enable robust and reliable assays that can be miniaturized and multiplexed.